But beneath the selloff, something unusual has emerged.<\/p>\n
Novo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It’s priced like a slow-growth legacy pharma stock.<\/p>\n
NVO Stock Now Trades At A Fraction Of Peer Valuations<\/p>\n
At just 10.6x earnings, NVO stock trades at a dramatic discount to both obesity-drug rival Eli Lilly and Company and broader pharma peers.<\/p>\n
CompanyP\/E Ratio (TTM)Earnings YieldNovo Nordisk10.6×9.42%Eli Lilly45.4×2.20%Vertex Pharmaceuticals31.8×3.14%Pfizer20.0x5.01%<\/p>\n
Data Source: Benzinga Pro<\/a><\/p>\n This gap is striking.<\/p>\n The market is no longer pricing Novo Nordisk as the creator of the GLP-1 obesity drug category. It’s pricing it as if its leadership has already peaked.<\/p>\n Expectations Have Reset \u2014 But The Opportunity Hasn’t Disappeared<\/p>\n The selloff reflects concerns over competition, pricing pressure, and slowing growth expectations. But valuation compression of this magnitude often signals a shift in expectations rather than a collapse in long-term relevance.<\/p>\n Novo Nordisk still controls one of the most important drug platforms in modern healthcare. The global obesity drug market is expected to expand dramatically over the next decade.<\/p>\n At a 9.4% earnings yield, the stock now reflects far more pessimism than optimism.<\/p>\n From Hypergrowth Premium To Deep-Value Setup<\/p>\n Novo Nordisk’s collapse has erased its growth premium and replaced it with a valuation typically reserved for declining businesses.<\/p>\n That reset may prove to be the real story.<\/p>\n Because when market leaders fall this far, the opportunity often isn’t in what they’ve lost \u2014 but in how little investors are now willing to pay for what they still control.<\/p>\n Photo: Shutterstock<\/p>\n